Video
Author(s):
Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer.
Martin Dietrich, MD, PhD, assistant professor, University of Central Florida, fellow, American College of Physicians, Florida Cancer Specialists & Research Institute, discusses future research directions for the treatment of patients with lung cancer.
A potentially practice-changing trial is the ongoing phase 3 LAURA study (NCT03521154), which is examining the efficacy and safety of osimertinib (Tagrisso) following chemoradiation in patients with stage III unresectable non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations, according to Dietrich. Based on data from the phase 3 PACIFIC trial (NCT02125461), it is clear that this subset of patients derives some benefit from additional treatment in this setting, Dietrich adds.